although
guarante
success
infect
entri
host
cell
critic
stage
life
viru
insid
cell
viru
still
need
overcom
hostil
environ
evad
immun
respons
subvert
rang
cellular
protein
pathway
facilit
replic
howev
find
permiss
cell
deliv
genet
inform
cytoplasm
case
nucleu
first
necessari
step
viral
infect
least
two
import
implic
prophylact
andor
therapeut
perspect
first
block
viral
entri
stop
infect
earli
prevent
viral
replic
second
mani
virus
exploit
cellular
endocyt
mechan
initi
intern
infect
cell
mechan
inhibit
pathway
may
affect
mani
differ
virus
greatli
expand
current
limit
antivir
portfolio
well
establish
initi
attach
cell
surfac
mani
virus
envelop
nonenvelop
exploit
chang
environment
condit
ph
interact
cellular
receptor
activ
proteolyt
enzym
trigger
conform
chang
key
protein
mediat
cell
membran
penetr
envelop
virus
viru
lipid
bilay
need
fuse
cellular
limit
membran
either
plasma
membran
membran
endocyt
organel
releas
viral
genom
mediat
viral
envelop
protein
nonenvelop
virus
genom
releas
affect
viral
capsid
protein
trigger
cell
membran
penetr
genom
releas
virus
fuse
directli
plasma
membran
major
use
endocyt
mechan
reach
intracellular
compart
clathrinmedi
endocytosi
cme
caveolinmedi
endocytosi
macropinocytosi
phagocytosi
current
best
character
pathway
cme
particular
exploit
numer
virus
includ
alphavirus
flavivirus
orthomyxovirus
rhabdovirus
macropinocytosi
link
uptak
larger
virus
poxvirus
filovirus
fit
clathrinco
vesicl
thu
inhibit
pathway
might
expect
impact
rang
differ
virus
review
summar
main
therapeut
approach
target
differ
stage
viral
entri
figur
either
inhibit
virusspecif
interact
block
conserv
cellular
mechan
virus
exploit
enter
cell
latter
tactic
indic
chang
focu
viral
therapeut
combin
tradit
approach
direct
specif
virus
novel
celltarget
strategi
broadspectrum
potenti
first
step
viral
entri
viru
adhes
cell
surfac
regardless
requir
engag
specif
receptor
virus
often
use
nonspecif
electrostat
interact
neg
charg
sugar
attach
cell
surfac
encount
specif
entri
receptor
neg
charg
heparan
sulfat
proteoglycan
hspg
express
surfac
eukaryot
cell
shown
requir
bind
mani
virus
includ
human
immunodefici
viru
hiv
herp
simplex
viru
hsv
human
cytomegaloviru
hcmv
human
papilloma
viru
hpv
respiratori
syncyti
viru
rsv
flavivirus
inhibit
interact
develop
decoy
particl
mimick
molecul
heparin
sulfat
polysaccharid
sulfon
acidco
nanoparticl
effect
prevent
infect
vitro
howev
limit
efficaci
seen
vivo
possibl
owe
poor
bioavail
formul
highmolecularweight
molecul
high
degre
sulfat
highest
antivir
activ
vitro
compound
tend
bind
plasma
protein
poor
bioavail
convers
lowmolecularweight
compound
better
bioavail
effect
vivo
also
associ
higher
cytotox
possibl
owe
deterg
effect
cellular
membran
virucid
activ
may
also
requir
increas
vivo
efficaci
cagno
et
al
shown
nanoparticl
carri
long
flexibl
linker
mimick
hspg
simultan
bind
multipl
site
viru
caus
perman
distort
virion
structur
virucid
activ
suffici
inhibit
rsv
infect
mice
suggest
particl
mimick
neg
charg
cellular
surfac
virus
bind
potenti
effect
antivir
long
includ
capac
inactiv
viral
infect
import
note
sulfat
polysaccharid
also
known
anticoagul
activ
deriv
exist
show
properti
vivo
therapeut
dose
eg
fucoidan
galactan
xylomannan
molecul
target
common
cellular
compon
also
potenti
interfer
attach
broadspectrum
antivir
activ
cyanovirinn
natur
occur
lectin
shown
inhibit
attach
hiv
ebola
viru
ebov
cell
like
bind
highmannos
oligosaccharid
viral
glycoprotein
mode
action
may
prevent
infect
virus
though
remain
test
vivo
efficaci
often
involv
viru
adhes
cell
surfac
neg
charg
sugar
associ
cell
surfac
glycoprotein
glycolipid
also
act
viru
receptor
eg
sialic
acid
influenza
enabl
interact
suffici
strength
allow
intern
viru
endocytosi
may
case
flavivirus
filovirus
viru
celltarget
approach
studi
prevent
interact
influenza
hemagglutinin
ha
sialic
acid
sa
glycoprotein
glycolipid
receptor
virustarget
strategi
includ
use
proteas
inhibitor
block
process
ha
peptid
small
molecul
interfer
ha
bind
sa
promis
celltarget
strategi
attach
inhibitor
recombin
protein
made
sialidas
catalyt
domain
remov
sa
influenza
receptor
mucos
cellsurfac
anchor
sequenc
compound
highli
potent
vitro
ic
nm
shown
nontox
cell
effect
vivo
administ
pre
postexposur
phase
ii
trial
show
reduct
viral
load
day
administr
mgkgday
phase
iii
trial
ongo
comprehens
overview
inhibitor
interact
present
cellsurfac
viru
receptor
maraviroc
fda
approv
current
drug
inhibit
viral
entri
target
major
coreceptor
requir
hiv
infect
cell
maraviroc
develop
pfizer
screen
compound
librari
subsequ
addit
screen
improv
activ
pharmacolog
properti
initi
hit
compound
combin
least
two
addit
antiretrovir
drug
maraviroc
current
use
hivinfect
patient
show
resist
compound
limit
develop
resist
observ
frequenc
clear
usual
associ
multipl
mutat
hiv
envelop
protein
gener
caus
signific
decreas
viral
fit
notion
viral
adapt
overcom
inhibitor
act
cellular
target
weaken
viru
potenti
signific
interest
advantag
hosttarget
antivir
strategi
altern
tactic
inhibit
synthesi
cellular
membran
glycoprotein
function
receptor
specif
virus
cyclotriazadisulfonamid
cada
smallmolecul
inhibitor
hiv
replic
found
specif
inhibit
synthesi
hiv
receptor
bind
protein
signal
sequenc
translocon
cotransl
insert
nascent
protein
er
membran
decreas
level
render
potenti
host
cell
refractori
infect
presum
virus
use
receptor
whether
approach
effect
vivo
whether
develop
inhibit
synthesi
broader
rang
viru
receptor
remain
seen
see
discuss
evid
compound
inhibit
synthesi
specif
cellsurfac
protein
inhibit
interact
viru
target
cell
also
one
main
mode
action
antibodi
identif
gener
antibodi
remain
major
strategi
antivir
immunotherapi
develop
small
molecul
mimic
effect
antibodi
administ
oral
also
potenti
scientist
janssen
develop
approach
start
identif
broadli
neutral
antibodi
target
conserv
region
stem
influenza
ha
use
displac
screen
strategi
identifi
small
molecul
could
bind
region
antibodi
medicin
chemistri
promis
hit
led
compound
benzylpiperazin
deriv
abl
inhibit
influenza
infect
cultur
human
bronchial
epitheli
cell
mous
model
encouragingli
protect
lethal
challeng
seen
oral
administr
latter
model
viru
receptor
found
cell
surfac
virus
also
interact
receptor
insid
endolysosom
compart
follow
endocytosi
exampl
ebov
use
lysosom
protein
niemann
pick
lassa
fever
viru
shown
interact
anoth
lysosom
protein
antibodi
target
interact
complic
intracellular
local
receptor
howev
excit
technolog
recent
expand
viral
infect
develop
bispecif
antibodi
link
variabl
region
antibodi
recogn
ebov
glycoprotein
gp
glycan
cap
variabl
region
antibodi
recogn
either
bind
region
gp
wec
et
al
show
bispecif
antibodi
bound
ebov
intern
endolysosom
compart
potent
block
ebola
interact
intracellular
receptor
strategi
alreadi
test
hiv
shown
protect
mice
even
administ
day
challeng
ebov
smallmolecul
inhibitor
accumul
endosom
compart
like
piperazinederiv
also
effect
block
ebov
infect
vitro
first
induc
cholesterol
accumul
lysosom
latter
directli
interact
compound
also
develop
select
bind
nonenvelop
viru
capsid
protein
prevent
interact
cellular
receptor
uncoat
one
exampl
enteroviru
capsid
inhibitor
pocapavir
test
investig
drug
treat
neonat
viral
sepsi
also
trial
spread
attenu
polioviru
vaccin
individu
pocapavir
capsid
binder
fit
hydrophob
pocket
viral
particl
prevent
conform
chang
requir
uncoat
disadvantag
select
drugresist
mutant
recent
conserv
interprotom
interfac
viral
capsid
critic
conform
chang
necessari
rna
releas
propos
altern
druggabl
target
compound
bind
interfac
shown
activ
larger
number
enterovirus
also
rhinovirus
though
abil
induc
resist
variant
yet
investig
tryptophan
dendrim
target
capsid
also
shown
antivir
potenti
vitro
prevent
viru
interact
co
receptor
heparan
sulfat
virus
penetr
directli
plasma
membran
endocytosi
essenti
step
entri
process
endocytosi
block
compound
interfer
signal
cascad
necessari
activ
endocytosi
inhibit
endocytosi
machineri
directli
signal
pathway
instanc
shown
requir
varieti
virus
inhibit
prevent
infect
vitro
similarli
vaccinia
viru
vv
entri
requir
signal
epiderm
growth
factor
receptor
egfr
serinethreonin
kinas
protein
kinas
c
kinas
addit
entri
least
vv
strain
sensit
tyrosin
kinas
inhibitor
genistein
howev
studi
effect
vivo
limit
evid
prevent
activ
reduc
pathogenesi
mice
infect
alphaviru
ross
river
like
due
postentri
effect
viru
replic
cellular
metabol
number
research
compound
exist
block
endocytosi
directli
includ
pitstop
inhibit
format
clathrinco
pit
well
dynasor
potent
deriv
interfer
dynamin
compound
shown
inhibit
entri
variou
virus
vitro
use
therapeut
antivir
studi
harper
et
al
show
inhibit
botulinum
neurotoxin
type
endocytosi
neuron
vitro
howev
vivo
administr
delay
onset
symptom
hour
infect
mice
encouragingli
anim
treat
show
sign
toxic
concentr
test
whether
higher
concentr
requir
see
stronger
effect
vivo
whether
higher
toxic
either
inhibit
endocytosi
offtarget
effect
whether
viru
infect
affect
requir
investig
sever
compound
includ
chlorpromazin
chloroquin
arbidol
also
shown
inhibit
endocytosi
antivir
effect
vitro
efficaci
vivo
yet
report
recent
studi
start
phenotyp
screen
repres
differ
viru
famili
identifi
two
compound
niclosamid
tyrphostin
broadspectrum
antivir
activ
affect
differ
stage
viru
replic
includ
endocytosi
like
mode
action
dissip
proton
gradient
inhibit
atp
synthesi
impact
multipl
cellular
pathway
howev
use
endocytosi
assay
abl
show
cme
alphaviru
semliki
forest
viru
fluoresc
label
transferrin
significantli
reduc
compound
pharmacokinet
properti
niclosamid
prevent
accumul
blood
tyrphostin
better
profil
show
abil
inhibit
zika
viru
infect
mous
model
tyrphostin
also
gener
tyrosin
kinas
inhibitor
like
affect
varieti
kinas
involv
viral
life
cycl
interestingli
tyrphostin
also
shown
inhibit
cme
prevent
interact
receptor
tyrosinebas
endocyt
signal
subunit
adaptor
complex
although
chemic
properti
tyrphostin
make
unlik
becom
drug
work
provid
proof
concept
entri
inhibitor
broadspectrum
antivir
activ
vitro
also
exhibit
antivir
activ
vivo
envelop
virus
fusion
next
necessari
step
allow
viru
releas
genom
cytoplasm
fusion
mediat
viral
encod
envelop
glycoprotein
display
virion
surfac
virus
requir
cellular
cue
induc
conform
chang
envelop
glycoprotein
initi
fusion
cellular
membran
case
plasma
membran
mani
virus
endosom
membran
virus
fuse
cell
surfac
hiv
receptor
engag
provid
cue
initi
envelop
glycoprotein
conform
chang
fusion
mani
virus
common
cue
acid
ph
endosom
environ
weak
base
includ
antimalari
drug
chloroquin
carboxyl
ionophor
monensin
inhibit
endosom
acidif
block
infect
wide
rang
virus
vitro
except
amantadin
studi
test
efficaci
vivo
weak
base
amantadin
amantadin
analogu
use
influenza
viru
infect
activ
direct
inhibit
viral
protein
rather
inhibit
endosom
acidif
virus
rapidli
evolv
resist
altern
cue
low
ph
proteolyt
cleavag
envelop
protein
endosom
proteas
use
filovirus
ebov
coronavirus
ebov
proteolyt
cleavag
endolysosom
cathepsin
essenti
gener
form
envelop
glycoprotein
bind
inhibitor
proteas
effect
abrog
ebov
infect
although
none
compound
current
approv
use
human
select
remain
issu
recent
role
twopor
calcium
channel
ebov
infect
shown
exact
role
yet
clear
like
control
cue
endolysosom
environ
necessari
ebov
fusion
interestingli
small
molecul
target
inhibit
ebov
infect
vitro
vivo
antagonist
includ
tetrandrin
also
inhibit
mer
coronavirus
similarli
apilimod
compound
target
pikfyv
involv
endosom
traffick
also
inhibit
ebov
infect
block
transport
ebola
particl
endolysosom
whether
compound
act
virus
penetr
late
endosom
remain
unclear
elev
endosom
potassium
may
also
provid
cue
activ
fusion
protein
bunyavirus
influenza
virus
infect
restrict
compound
inhibit
endosom
potassium
channel
togeth
studi
indic
combin
perturb
endocyt
system
might
offer
effect
approach
inhibit
rang
differ
virus
virusspecif
fusion
inhibitor
also
exist
enfuvirtid
use
combin
antiretrovir
therapi
treatment
hiv
peptid
bind
heptad
repeat
region
subunit
hiv
envelop
glycoprotein
prevent
format
socal
stabl
sixhelix
bundl
crucial
membran
fusion
fusion
inhibitor
stabil
metast
conform
rsv
fusion
protein
also
develop
though
none
current
approv
use
number
clinic
trial
peptid
block
fusion
paramyxovirus
includ
measl
nipah
hendra
virus
interf
viral
envelop
protein
also
develop
shown
antivir
activ
vivo
similar
approach
use
peptid
small
molecul
also
shown
promis
flavivirus
west
nile
dengu
virus
altern
approach
inhibit
fusion
interfer
biophys
properti
membran
compound
intercal
cellular
membran
alter
rigid
curvatur
achiev
certain
lipid
tissu
cultur
system
similar
effect
may
underli
action
cellular
protein
call
interferoninduc
transmembran
protein
ifitm
although
exact
mode
action
protein
three
human
ifitm
remain
unclear
effect
extraordinari
varieti
virus
suggest
interf
compositionbiophys
properti
cellular
membran
involv
viru
entri
potent
broadspectrum
antivir
strategi
howev
recent
work
buchries
et
al
indic
ifitm
express
interfer
placent
develop
inhibit
syncytinmedi
syncytiotrophoblast
format
indic
protein
interfer
cellular
fusion
reaction
whether
impact
fusion
event
intracellular
membran
fusion
process
remain
establish
use
phenotyp
screen
other
identifi
number
compound
biophys
properti
like
intercal
endosom
membran
prevent
fusion
possibl
mode
action
select
estrogen
receptor
modul
serm
similar
amphipath
compound
includ
amiodaron
amodiaquin
although
possibl
compound
may
also
alter
endosom
ph
howev
concentr
requir
achiev
similar
antivir
effect
vivo
like
high
risk
side
effect
signific
interf
viral
rather
cellular
membran
also
promis
broadspectrum
antivir
approach
envelop
virus
small
molecul
oxid
unsatur
phospholipid
cellular
viral
membran
like
alter
membran
curvatur
fluiditi
prevent
fusion
interestingli
affect
cellular
viral
membran
latter
significantli
affect
like
cellular
membran
rapidli
replac
damag
lipid
properti
virus
share
make
effect
vitro
wide
varieti
virus
includ
influenza
limit
toxic
unfortun
littl
effect
seen
vivo
owe
short
halflif
hour
low
concentr
compound
serum
furthermor
need
light
activ
limit
applic
vivo
nevertheless
analogu
improv
stabil
pharmacokinet
develop
host
cell
entri
crucial
step
virus
prevent
entri
provid
clear
earli
opportun
control
infect
virus
use
conserv
cellular
pathway
entri
target
cellular
protein
rather
viral
protein
emerg
promis
antivir
strategi
inde
mani
approach
investig
past
year
target
host
rather
viral
compon
even
target
highli
select
one
specif
viru
case
maraviroc
line
recent
trend
develop
antivir
strategi
date
smallmolecul
interfer
viral
infect
tend
focu
specif
virus
viral
protein
virus
hiv
hcv
herp
exampl
approach
effect
case
hiv
least
combin
compound
target
key
viral
enzym
essenti
complet
viral
life
cycl
eg
hiv
polencod
revers
transcriptas
integras
proteas
control
viru
replic
infect
patient
substanti
improv
longev
life
qualiti
adopt
pre
postexposur
prophylact
prevent
viru
infect
similarli
nucleosid
analogu
proteas
inhibitor
activ
hcv
potenti
cure
would
otherwis
lifelong
chronic
infect
often
result
cirrhosi
liver
cancer
treatabl
liver
transplant
though
highli
success
drug
limit
treatment
singl
virus
prone
viral
resist
mutat
render
ineffect
convers
drug
avail
use
major
virus
major
concern
given
increas
emerg
reemerg
new
pathogen
often
zoonot
infect
eg
sar
mer
enlarg
geograph
distribut
insectvector
virus
caus
environment
chang
eg
zika
dengu
circumst
target
host
cell
pathway
oppos
viral
protein
viabl
option
control
infect
one
argument
approach
potenti
toxic
target
host
cell
pathway
toxic
could
due
inhibit
critic
cellular
pathway
well
offtarget
effect
howev
viru
infect
might
benefit
approach
establish
acut
infect
drug
administr
could
short
day
moreov
drug
current
market
rang
diseas
target
host
cell
pathway
limit
accept
side
effect
anoth
argument
virustarget
antivir
seem
potent
celltarget
one
concern
counterbalanc
potenti
broadspectrum
effect
mani
celltarget
approach
may
critic
rapidli
contain
emerg
virus
lower
potenc
compound
might
stop
viru
infect
complet
sever
studi
indic
gener
capac
reduc
viral
load
give
patient
better
chanc
establish
effect
immun
control
applic
antiretrovir
therapi
compound
target
entri
replic
could
use
combin
exampl
compound
inhibit
cme
could
administ
togeth
compound
inhibit
macropinocytosi
andor
endosom
acidif
order
broaden
rang
virus
affect
andor
increas
effect
treatment
although
focus
viru
entri
target
cellular
pathway
erassoci
glycoprotein
synthesi
also
offer
excit
potenti
broadspectrum
antivir
develop
could
broaden
potenti
combin
therapi
strategi
could
also
reduc
toxic
allow
use
lower
concentr
compon
complex
formul
mani
success
approach
describ
vitro
outstand
question
whether
also
effect
vivo
particular
hosttarget
approach
import
determin
safe
threshold
separ
effect
decreas
viral
load
toxic
limit
vivo
efficaci
mani
treatment
date
may
due
pharmacokinet
bioavail
compound
possibl
limit
rang
condit
gener
test
vivo
due
cost
logist
restrict
anim
studi
limit
avail
adequ
small
model
recapitul
diseas
also
contribut
problem
work
remain
done
approv
drug
like
maraviroc
enfuvirtid
suggest
target
viral
entri
promis
antivir
strategi
warrant
investig
integr
differ
disciplin
virolog
medicin
chemistri
